A Phase 1 interventional study of belatacept and Placebo in Transplantation, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-22.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belatacept 50 mg subcutaneous (SC) injection
Drug: belatacept
Belatacept 100 mg SC injection
Drug: belatacept
Belatacept 125 mg SC injection
Drug: belatacept
2 SC injections of 75 mg Belatacept
Drug: belatacept
2 SC injections of 100 mg Belatacept
Drug: belatacept
2 SC injections of 125 mg Belatacept
Drug: belatacept
125 mg Belatacept intravenous (IV) injection
Drug: belatacept
SC injection of placebo solution
Drug: Placebo
single dose, 116 days
Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
Maximum Observed Serum Concentration (Cmax) of Belatacept
Maximum observed serum concentration (Cmax) values were derived from serum concentration versus time data and reported in micrograms per milliliter (ug/mL).
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Time of Maximum Observed Serum Concentration (Tmax) of Belatacept
Time of maximum observed serum concentration (Tmax) values were derived from serum concentration versus time data for all participants treated with Belatacept.
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept
Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug\*h/mL).
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept
Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug\*h/mL)
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Serum Half-life (T-HALF) of Belatacept
Serum half-life (T-HALF) was determined from serum concentration versus time data and was reported in hours.
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Apparent Total Body Clearance (CLT/F) of SC Belatacept
Apparent total body clearance (CLT/F) was derived from serum concentration versus time data for all participants who received subcutaneous (SC) Belatacept injections. Units reported in milliliters per hour (mL/h).
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Total Body Clearance (CLT) of IV Belatacept
Total body clearance (CLT) was derived from serum concentration versus time data for all participants that were treated with IV Belatacept. Units reported in milliliters per hour (mL/h)
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Volume of Distribution at Steady State (VSS) for IV Belatacept
Volume of distribution at steady state (VSS) was derived from serum concentration versus time data for all participants treated with IV Belatacept.
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Apparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept
Apparent volume of distribution at steady state (Vss/F) was derived from concentration versus time data for all participants treated with subcutaneous (SC) Belatacept.
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Effect of Number of Injection Sites on Subcutaneous Belatacept Absorption
AUC(0-T) and AUC(INF) for Belatacept were derived from serum concentration versus time data to assess the effect of number of injection sites on the subcutaneous absorption of Belatacept. All treatments were dose-normalized to 50mg. Adjusted geometric means reported in microgram hours per milliliter (ug\*h/mL). AUC(0-T) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration. AUC(INF) = Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time.
Time frame: Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116
Number of Participants With Vital Sign Abnormalities
Vital signs (body temperature, respiratory rate, seated blood pressure, and heart rate) were recorded at screening. All significant findings were evaluated by the investigator, and all abnormalities were listed.
Time frame: 1 day pre-dose, Days 1, 2, 5, 14, 28, 42, 86 and 116
Number of Participants With Injection Site Reactions
Participants were assessed for erythema, heat, pain, pruritis and swelling at the injection sites and were characterized by the investigator as mild, moderate or severe reactions.
Time frame: 0.5, 2, 6 and 24 hours post-dose, Days 3, 4, 5, 6, 7, 8, 14, 21 and 116
Number of Participants With Physical Examination Abnormalities
All clinically significant deviations from normal physical examinations were reported.
Time frame: Days 1, 2, 5, 14, 28, 42, 86, 116
Number of Participants With Electrocardiogram (ECG) Abnormalities
Participants underwent a 12-lead ECG assessment at Screening (Day 1) and Study Discharge (Day 116). All investigator-assessed ECG abnormalities were reported.
Time frame: Days 1 and 116
Number of Participants With Marked Hematology Laboratory Abnormalities
LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Hemoglobin (grams per deciliter:g/dL): \<0.85\*Pre-Rx. Hematocrit (%): \<0.85\*Pre-Rx. Platelet Count (\*10\^9 cells per liter:c/L): \<0.85\*LLN or \>1.5\*ULN (if Pre-Rx\<LLN, use \<0.85\*Pre-Rx). Leukocytes (\*10\^3 cells per microliter: c/uL): \<0.9\*LLN, \>1.2\*ULN (if Pre-Rx\<LLN, use \<0.85\*Pre-Rx or \>ULN, if Pre-Rx\>ULN, use \>1.15\*Pre-Rx or \<LLN) Neutrophils+Bands (\*10\^3 c/uL): \<=1.500. Lymphocytes (\*10\^3 c/uL): \<0.750 or \>7.500. Monocytes (\*10\^3 c/uL): \>2.000. Basophils (\*10\^3 c/uL): \>0.400. Eosinophils (\*10\^3 c/uL): \>0.750.
Time frame: Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116
Number of Participants With Marked Serum Chemistry Abnormalities
LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): \>1.25\*ULN (if Pre-Rx\>ULN, use \>1.25\*Pre-Rx). Bilirubin (milligrams per deciliter: mg/dL): \>1.1\*ULN (if Pre-Rx\>ULN, use \>1.25\*Pre-Rx). Blood Urea Nitrogen (mg/dL): \>1.1\*ULN (if Pre-Rx\>ULN, use \>1.2\*Pre-Rx). Creatinine (mg/dL): \>1.33\*Pre-Rx. Sodium (milliequivalents per Liter: mEq/L): \<0.95\*LLN, \>1.05\*ULN (if Pre-Rx\<LLN: \<0.95\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.05\*Pre-Rx, \<LLN). Potassium(mEq/L), Chloride (mEq/L), Calcium(mg/dL): \<0.9\*LLN, \>1.1\*ULN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.1\*Pre-Rx, \<LLN). Phosphorus (mg/dL): \<0.85\*LLN, \>1.25\*ULN (if Pre-Rx\<LLN, \<0.85\*Pre-Rx, \>ULN. if Pre-Rx\>ULN: \>1.25\*Pre-Rx, \<LLN).
Time frame: Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116
Number of Participants With Marked Laboratory Abnormalities
LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Glucose (mg/dL): \<0.8\*LLN, \>1.5\*ULN (if Pre-Rx\<LLN: \<0.8\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>2.0\*Pre-Rx, \<LLN). Protein (grams per deciliter: g/dL): \<0.9\*LLN, \>1.1\*ULN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.1\*Pre-Rx, \<LLN). Albumin (g/dL): \<0.9\*LLN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx). Uric Acid (mg.dL): \>1.2\*ULN (if Pre-Rx\>ULN: \>1.25\*Pre-Rx). Lactate Dehydrogenase (U/L): \>1.25\*ULN (if Pre-Rx\>ULN: \>1.5\*Pre-Rx)
Time frame: Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116
Number of Participants With Positive Immunogenicity to Belatacept
The number of participants with positive immunogenicity to Belatacept was reported for each arm. Positive immunogenicity was defined as the presence of a positive antibody response generated against Belatacept.
Time frame: Days 1, 14, 28, 42, 56, 86, 116
| Milestone | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 6 | 5 | 5 | 10 | 6 |
| Completed | 4 | 5 | 5 | 5 | 5 | 5 | 10 | 5 |
| Not completed | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Injection syringe leaked during dosing | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Maximum observed serum concentration (Cmax) values were derived from serum concentration versus time data and reported in micrograms per milliliter (ug/mL).
| ug/mL | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion |
|---|---|---|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of Belatacept | 3.9 ± 30 | 6.2 ± 34 | 8.5 ± 50 | 11.1 ± 19 | 14.5 ± 16 | 14.5 ± 18 | 42.4 ± 16 |
Time of maximum observed serum concentration (Tmax) values were derived from serum concentration versus time data for all participants treated with Belatacept.
| hours | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion |
|---|---|---|---|---|---|---|---|
| Time of Maximum Observed Serum Concentration (Tmax) of Belatacept | 84 (36 to 96) | 60 (48 to 120) | 96 (48 to 144) | 60 (36 to 96) | 60 (24 to 84) | 72 (60 to 96) | 0.5 (0.2 to 2.0) |
Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug\*h/mL).
| ug*h/mL | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion |
|---|---|---|---|---|---|---|---|
| Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept | 2587 (2132 to 3139) | 1848 (1523 to 2242) | 2371 (1954 to 2876) | 2703 (2228 to 3280) | 2650 (2184 to 3215) | 2193 (1807 to 2660) | 3023 (2637 to 3466) |
Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug\*h/mL)
| ug*h/mL | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion |
|---|---|---|---|---|---|---|---|
| Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept | 2639 (2172 to 3205) | 1851 (1524 to 2248) | 2380 (1959 to 2891) | 2719 (2238 to 3303) | 2666 (2194 to 3238) | 2201 (1812 to 2673) | 3031 (2642 to 3478) |
Serum half-life (T-HALF) was determined from serum concentration versus time data and was reported in hours.
| hours | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion |
|---|---|---|---|---|---|---|---|
| Serum Half-life (T-HALF) of Belatacept | 112 ± 25.7 | 100 ± 10.1 | 135 ± 47.6 | 158 ± 46.9 | 161 ± 45.3 | 150 ± 43.6 | 130 ± 27.6 |
Apparent total body clearance (CLT/F) was derived from serum concentration versus time data for all participants who received subcutaneous (SC) Belatacept injections. Units reported in milliliters per hour (mL/h).
| mL/h | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections |
|---|---|---|---|---|---|---|
| Apparent Total Body Clearance (CLT/F) of SC Belatacept | 47.4 ± 27 | 67.5 ± 34 | 52.5 ± 31 | 46.0 ± 26 | 46.9 ± 21 | 56.8 ± 20 |
Total body clearance (CLT) was derived from serum concentration versus time data for all participants that were treated with IV Belatacept. Units reported in milliliters per hour (mL/h)
| mL/h | Belatacept 125 mg Intravenous Infusion |
|---|---|
| Total Body Clearance (CLT) of IV Belatacept | 41.2 ± 21 |
Volume of distribution at steady state (VSS) was derived from serum concentration versus time data for all participants treated with IV Belatacept.
| Liters | Belatacept 125 mg Intravenous Infusion |
|---|---|
| Volume of Distribution at Steady State (VSS) for IV Belatacept | 7.3 ± 1.27 |
Apparent volume of distribution at steady state (Vss/F) was derived from concentration versus time data for all participants treated with subcutaneous (SC) Belatacept.
| Liters | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections |
|---|---|---|---|---|---|---|
| Apparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept | 10.79 ± 31.02 | 15.30 ± 28.79 | 14.12 ± 36.63 | 12.75 ± 14.20 | 13.34 ± 13.77 | 15.82 ± 11.92 |
AUC(0-T) and AUC(INF) for Belatacept were derived from serum concentration versus time data to assess the effect of number of injection sites on the subcutaneous absorption of Belatacept. All treatments were dose-normalized to 50mg. Adjusted geometric means reported in microgram hours per milliliter (ug\*h/mL). AUC(0-T) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration. AUC(INF) = Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time.
| ug*h/mL | 1 Injection Site | 2 Injection Sites |
|---|---|---|
| AUC(0-T) | 898 (794 to 1017) | 1002 (885 to 1134) |
| AUC(INF) | 906 (799 to 1027) | 1007 (888 to 1142) |
Vital signs (body temperature, respiratory rate, seated blood pressure, and heart rate) were recorded at screening. All significant findings were evaluated by the investigator, and all abnormalities were listed.
| participants | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Vital Sign Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Participants were assessed for erythema, heat, pain, pruritis and swelling at the injection sites and were characterized by the investigator as mild, moderate or severe reactions.
| participants | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo |
|---|---|---|---|---|---|---|---|---|
| mild reaction | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| moderate reaction | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| severe reaction | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
All clinically significant deviations from normal physical examinations were reported.
| participants | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Physical Examination Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Participants underwent a 12-lead ECG assessment at Screening (Day 1) and Study Discharge (Day 116). All investigator-assessed ECG abnormalities were reported.
| participants | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo |
|---|---|---|---|---|---|---|---|---|
| Screening (Day 1) | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 |
| Study Discharge (Day 116) | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 |
LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Hemoglobin (grams per deciliter:g/dL): \<0.85\*Pre-Rx. Hematocrit (%): \<0.85\*Pre-Rx. Platelet Count (\*10\^9 cells per liter:c/L): \<0.85\*LLN or \>1.5\*ULN (if Pre-Rx\<LLN, use \<0.85\*Pre-Rx). Leukocytes (\*10\^3 cells per microliter: c/uL): \<0.9\*LLN, \>1.2\*ULN (if Pre-Rx\<LLN, use \<0.85\*Pre-Rx or \>ULN, if Pre-Rx\>ULN, use \>1.15\*Pre-Rx or \<LLN) Neutrophils+Bands (\*10\^3 c/uL): \<=1.500. Lymphocytes (\*10\^3 c/uL): \<0.750 or \>7.500. Monocytes (\*10\^3 c/uL): \>2.000. Basophils (\*10\^3 c/uL): \>0.400. Eosinophils (\*10\^3 c/uL): \>0.750.
| participants | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo |
|---|---|---|---|---|---|---|---|---|
| Hemoglobin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelet Count | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutrophils + Bands (absolute) | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Lymphocytes (absolute) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Monocytes (absolute) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basophils (absolute) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils (absolute) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): \>1.25\*ULN (if Pre-Rx\>ULN, use \>1.25\*Pre-Rx). Bilirubin (milligrams per deciliter: mg/dL): \>1.1\*ULN (if Pre-Rx\>ULN, use \>1.25\*Pre-Rx). Blood Urea Nitrogen (mg/dL): \>1.1\*ULN (if Pre-Rx\>ULN, use \>1.2\*Pre-Rx). Creatinine (mg/dL): \>1.33\*Pre-Rx. Sodium (milliequivalents per Liter: mEq/L): \<0.95\*LLN, \>1.05\*ULN (if Pre-Rx\<LLN: \<0.95\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.05\*Pre-Rx, \<LLN). Potassium(mEq/L), Chloride (mEq/L), Calcium(mg/dL): \<0.9\*LLN, \>1.1\*ULN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.1\*Pre-Rx, \<LLN). Phosphorus (mg/dL): \<0.85\*LLN, \>1.25\*ULN (if Pre-Rx\<LLN, \<0.85\*Pre-Rx, \>ULN. if Pre-Rx\>ULN: \>1.25\*Pre-Rx, \<LLN).
| participants | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo |
|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Alanine Aminotransferase | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Bilirubin | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Blood Urea Nitrogen | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Creatinine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, Serum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, Serum | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Chloride, Serum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phosphorus, Inorganic | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Glucose (mg/dL): \<0.8\*LLN, \>1.5\*ULN (if Pre-Rx\<LLN: \<0.8\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>2.0\*Pre-Rx, \<LLN). Protein (grams per deciliter: g/dL): \<0.9\*LLN, \>1.1\*ULN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx, \>ULN. If Pre-Rx\>ULN: \>1.1\*Pre-Rx, \<LLN). Albumin (g/dL): \<0.9\*LLN (if Pre-Rx\<LLN: \<0.9\*Pre-Rx). Uric Acid (mg.dL): \>1.2\*ULN (if Pre-Rx\>ULN: \>1.25\*Pre-Rx). Lactate Dehydrogenase (U/L): \>1.25\*ULN (if Pre-Rx\>ULN: \>1.5\*Pre-Rx)
| participants | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo |
|---|---|---|---|---|---|---|---|---|
| Glucose, Fasting Serum | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Protein, Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Uric Acid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lactate Dehydrogenase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of participants with positive immunogenicity to Belatacept was reported for each arm. Positive immunogenicity was defined as the presence of a positive antibody response generated against Belatacept.
| participants | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion |
|---|---|---|---|---|---|---|---|
| Number of Participants With Positive Immunogenicity to Belatacept | 4 | 5 | 5 | 5 | 5 | 5 | 10 |
Collected over From Day 1 until 30 days post discontinuation of dosing, up to August 2008 (approximately 8 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belatacept 50mg SC | — | 0/5 (0%) | 2/5 (40%) |
| Belatacept 100mg SC | — | 0/5 (0%) | 3/5 (60%) |
| Belatacept 125mg SC | — | 0/5 (0%) | 3/5 (60%) |
| Belatacept 150mg SC | — | 0/6 (0%) | 4/6 (66.7%) |
| Belatacept 200mg SC | — | 0/5 (0%) | 2/5 (40%) |
| Belatacept 250mg SC | — | 0/5 (0%) | 2/5 (40%) |
| Belatacept 125mg IV | — | 0/10 (0%) | 7/10 (70%) |
| PLACEBO | — | 0/6 (0%) | 1/6 (16.7%) |
| All Belatacept | — | 0/41 (0%) | 23/41 (56.1%) |
| Event | Belatacept 50mg SC | Belatacept 100mg SC | Belatacept 125mg SC | Belatacept 150mg SC | Belatacept 200mg SC | Belatacept 250mg SC | Belatacept 125mg IV | PLACEBO | All Belatacept |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/5 | 2/5 | 2/5 | 0/6 | 1/5 | 0/5 | 3/10 | 0/6 | 8/41 |
| NauseaGastrointestinal disorders | 0/5 | 0/5 | 1/5 | 2/6 | 0/5 | 0/5 | 0/10 | 0/6 | 3/41 |
| Feeling hotGeneral disorders | 0/5 | 0/5 | 0/5 | 2/6 | 0/5 | 0/5 | 0/10 | 0/6 | 2/41 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/5 | 1/5 | 1/5 | 1/6 | 0/5 | 1/5 | 3/10 | 0/6 | 8/41 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/5 | 0/5 | 1/5 | 0/6 | 0/5 | 0/5 | 1/10 | 0/6 | 2/41 |
| Abdominal painGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 0/6 | 1/5 | 0/5 | 0/10 | 0/6 | 1/41 |
| Arthropod stingInjury, poisoning and procedural complications | 0/5 | 1/5 | 0/5 | 0/6 | 0/5 | 0/5 | 0/10 | 0/6 | 1/41 |
| Injection site inflammationGeneral disorders | 0/5 | 0/5 | 1/5 | 0/6 | 0/5 | 0/5 | 0/10 | 0/6 | 1/41 |
| Urinary tract infectionInfections and infestations | 0/5 | 1/5 | 0/5 | 0/6 | 0/5 | 0/5 | 0/10 | 0/6 | 1/41 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/5 | 0/5 | 0/5 | 0/6 | 0/5 | 0/5 | 0/10 | 0/6 | 1/41 |
| Age, Continuous(years) | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 30 ± 11 | 27 ± 12 | 28 ± 12 | 34 ± 18 | 31 ± 11 | 31 ± 10 | 32 ± 16 | 27 ± 6 | 30 ± 12 |
| Sex: Female, Male(Participants) | Belatacept 50 mg Subcutaneous Injection | Belatacept 100 mg Subcutaneous Injection | Belatacept 125 mg Subcutaneous Injection | Belatacept 150 mg Subcutaneous Injections | Belatacept 200 mg Subcutaneous Injections | Belatacept 250 mg Subcutaneous Injections | Belatacept 125 mg Intravenous Infusion | Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 2 | 2 | 3 | 2 | 2 | 4 | 21 |
| Male | 1 | 3 | 3 | 4 | 2 | 3 | 8 | 2 | 26 |
The record gives a start of Dec 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 8 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept